Reinforces its authority with eminent scientific advisors and board personnel of top-tier caliber at Dxcover
In a significant move to bolster its capabilities, Dxcover has announced the expansion of its leadership team. This strategic move is aimed at advancing the company's Multiomic Spectral Analysis (MOSA-Dx™) platform and preparing for US market commercialization.
Stacy Chick, an experienced global commercial life sciences executive, has joined Dxcover's ranks. Her expertise includes developing markets, building commercial operations, and scaling revenues at optimal reimbursement rates. Chick previously led area sales, operations, analytics, and market access teams at Sanofi. Moreover, she has successfully transitioned diagnostic innovations from research to commercial stage at Inivata and Kiyatec.
Marc Jones, a seasoned professional in diagnostics, software, and AI-powered platforms, has also joined Dxcover. Jones, previously the CEO of Altoida, focused on digital biomarkers for neurological diseases using artificial intelligence and real-world data. Notably, he has led the development of FDA-cleared and CE-marked products.
To further bolster its expertise, Dxcover has also expanded its Scientific Advisory Board (SAB). Professor Katy Peters MD PhD, a neurology and neurosurgery expert from Duke University Medical Center, has been appointed to Dxcover's SAB. Professor Peters is a leading expert in neuro-oncology and clinical trial design, with deep knowledge of brain cancer care pathways and translational research to bring diagnostic innovations to clinics.
Dr. Luke Pike MD DPhil, a radiation oncologist specializing in CNS malignancies from Memorial Sloan Kettering Cancer Center, is already a member of Dxcover's SAB. His expertise adds significant value to the team, particularly in the field of central nervous system cancers.
Professor Paul Brennan MB BChir FRCS(Ed) PhD, a brain cancer diagnostics expert from the University of Edinburgh, is also a member of Dxcover's SAB. His expertise in brain cancer diagnostics will be instrumental in Dxcover's mission.
In addition, Professor Emma Crosbie MBChB(Hons) PhD MRCOG, a gynaecological oncology expert from The University of Manchester, has been appointed to Dxcover's SAB. Her expertise in early detection and prevention of endometrial and ovarian cancers, coupled with her expertise in clinical trials and biomarker research for early detection strategies, will further strengthen Dxcover's capabilities.
Lastly, Professor William E. Fisher, Vice Chair of Clinical Affairs at Baylor College of Medicine’s Elkins Pancreas Center, provides expertise in pancreatic cancer diagnostics. His appointment to Dxcover's SAB reinforces the company's commitment to comprehensive oncology diagnostics.
The new appointments and additions to the SAB are instrumental for Dxcover's goal to expand access to its platform, broaden its diagnostic menu, pursue regulatory milestones, and deliver its technology into the hands of physicians and their patients globally.
[1] Stacy Chick joins Dxcover as a strategic advisor. (2022, March 22). Retrieved from https://www.businesswire.com/news/home/20220322005003/en/Stacy-Chick-Joins-Dxcover-as-a-Strategic-Advisor
[2] Marc Jones joins Dxcover as a strategic advisor. (2022, March 22). Retrieved from https://www.businesswire.com/news/home/20220322005004/en/Marc-Jones-Joins-Dxcover-as-a-Strategic-Advisor
[3] Dxcover expands SAB and Board of Directors. (2022, March 22). Retrieved from https://www.businesswire.com/news/home/20220322005005/en/Dxcover-Expands-SAB-and-Board-of-Directors
- Dxcover's new strategic advisor Stacy Chick brings expertise in developing markets, building commercial operations, and scaling revenues at optimal reimbursement rates, previously leading teams at Sanofi, Inivata, and Kiyatec.
- Marc Jones, a new strategic advisor to Dxcover, has a background in diagnostics, software, and AI-powered platforms, most recently serving as CEO of Altoida, where he focused on digital biomarkers for neurological diseases using artificial intelligence and real-world data.
- In an effort to bolster its expertise, Dxcover has expanded its Scientific Advisory Board (SAB), adding Professor Katy Peters MD PhD, a neurology and neurosurgery expert from Duke University Medical Center, Dr. Luke Pike MD DPhil, a radiation oncologist specializing in CNS malignancies from Memorial Sloan Kettering Cancer Center, Professor Paul Brennan MB BChir FRCS(Ed) PhD, a brain cancer diagnostics expert from the University of Edinburgh, Professor Emma Crosbie MBChB(Hons) PhD MRCOG, a gynaecological oncology expert from The University of Manchester, and Professor William E. Fisher, Vice Chair of Clinical Affairs at Baylor College of Medicine’s Elkins Pancreas Center.
- The expansion of Dxcover's leadership team and Scientific Advisory Board is part of the company's goal to expand access to its platform, broaden its diagnostic menu, pursue regulatory milestones, and deliver its technology into the hands of physicians and their patients globally – a commitment further reinforced by the appointments announced on March 22, 2022. (Dxcover expands SAB and Board of Directors, 2022)
In digital health and health tech, finance plays a crucial role in the pursuit of regulatory milestones and the broadening of diagnostic menus. Ultimately, the goal is to deliver technology into the hands of physicians and patients globally, improving medical-conditions care through innovative technology and business strategies. (Health tech, digital health, finance, business, technology, science, medical-conditions)
